Key Highlights: • Exclusive Partnership: TBD Pharmatech will be the sole supplier of CliCr® to Cristal Therapeutics. • Strategic Supply Security: The agreement secures a robust and high-quality supply of CliCr® for Cristal’s and its clients pipelines • Commitment to Innovation: Both companies reaffirm their commitment to advancing innovative solutions in pharmaceutical drug product development […]

As per 25 Jan 2023, Iris Biotech sells CliCr® and CliCr® reagents for non-GXP research purposes. For GXP applications, parties are to connect with Cristal Therapeutics. Read more information on https://www.iris-biotech.de/de/blog/potm-clicrr-an-innovative-click-reagent/

Maastricht, The Netherlands, 4 May 2022 – Cristal Therapeutics, a Dutch pharmaceutical company developing tailored nanomedicines for the treatment of cancer and other diseases with high unmet patient need, today announced the publication of the results of the clinical PICCOLO study in the peer-reviewed journal, Advanced Materials1. This first-of-its-kind study2, part funded by an EU Horizon […]

First joint CriVac® vaccine candidate to target receptor-binding domain of SARS-CoV-2 Evaluation of Cristal’s CliCr® and Intravacc’s OMV technology Bilthoven and Maastricht, the Netherlands, 6 January 2021 – Intravacc, a world leader in translational research and development of vaccines, and Cristal Therapeutics, a technology leader in enabling safer and more effective therapeutics, today announced a […]

Horizon 2020 INNOSUP grant allows the funding of a highly skilled and experienced researcher (Innovation Associate) to develop and implement state-of-art (bio)analytical methodologies for further understanding of the biological behaviour of CriPec® nanomedicines Maastricht, The Netherlands, 2nd July 2020 – Cristal Therapeutics, a phase 2 clinical-stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer […]